Repligen Future Growth
Future criteria checks 4/6
Repligen is forecast to grow earnings and revenue by 60.5% and 14.2% per annum respectively. EPS is expected to grow by 64.5% per annum. Return on equity is forecast to be 5% in 3 years.
Key information
60.5%
Earnings growth rate
64.5%
EPS growth rate
| Life Sciences earnings growth | 16.6% |
| Revenue growth rate | 14.2% |
| Future return on equity | 5.0% |
| Analyst coverage | Good |
| Last updated | 02 May 2024 |
Recent future growth updates
Recent updates
Repligen Corporation Just Missed Earnings - But Analysts Have Updated Their Models
May 03
Estimating The Intrinsic Value Of Repligen Corporation (NASDAQ:RGEN)
Apr 30Repligen (NASDAQ:RGEN) Has A Pretty Healthy Balance Sheet
Apr 15At US$206, Is Repligen Corporation (NASDAQ:RGEN) Worth Looking At Closely?
Feb 13Estimating The Intrinsic Value Of Repligen Corporation (NASDAQ:RGEN)
Jan 08Why We're Not Concerned About Repligen Corporation's (NASDAQ:RGEN) Share Price
Dec 19What Does Repligen Corporation's (NASDAQ:RGEN) Share Price Indicate?
Nov 01Is Repligen (NASDAQ:RGEN) Using Too Much Debt?
Oct 17Is There An Opportunity With Repligen Corporation's (NASDAQ:RGEN) 22% Undervaluation?
Sep 29Things Look Grim For Repligen Corporation (NASDAQ:RGEN) After Today's Downgrade
Aug 09Does Repligen (NASDAQ:RGEN) Have A Healthy Balance Sheet?
Jul 17Is There Now An Opportunity In Repligen Corporation (NASDAQ:RGEN)?
Jul 03With EPS Growth And More, Repligen (NASDAQ:RGEN) Makes An Interesting Case
Jun 19Calculating The Fair Value Of Repligen Corporation (NASDAQ:RGEN)
May 23Repligen (NASDAQ:RGEN) Seems To Use Debt Quite Sensibly
Apr 11Is Now An Opportune Moment To Examine Repligen Corporation (NASDAQ:RGEN)?
Mar 28We Ran A Stock Scan For Earnings Growth And Repligen (NASDAQ:RGEN) Passed With Ease
Mar 08Estimating The Intrinsic Value Of Repligen Corporation (NASDAQ:RGEN)
Feb 20Repligen (NASDAQ:RGEN) Seems To Use Debt Quite Sensibly
Jan 10Should You Think About Buying Repligen Corporation (NASDAQ:RGEN) Now?
Dec 28Is Repligen (NASDAQ:RGEN) A Risky Investment?
Oct 03Repligen: Now Best Biotech Nearby Cap-Gain Prospect
Sep 27Repligen partners with DRS daylight solutions
Sep 19When Should You Buy Repligen Corporation (NASDAQ:RGEN)?
Sep 19Do Repligen's (NASDAQ:RGEN) Earnings Warrant Your Attention?
Aug 23Repligen briefly turns positive after report of rejected takeover offer
Aug 11Earnings and Revenue Growth Forecasts
| Date | Revenue | Earnings | Free Cash Flow | Cash from Op | Avg. No. Analysts |
|---|---|---|---|---|---|
| 12/31/2026 | 859 | 134 | 169 | 191 | 4 |
| 12/31/2025 | 740 | 89 | 113 | 176 | 12 |
| 12/31/2024 | 638 | 46 | 75 | 141 | 13 |
| 3/31/2024 | 607 | 15 | 110 | 147 | N/A |
| 12/31/2023 | 639 | 42 | 75 | 114 | N/A |
| 9/30/2023 | 670 | 116 | 97 | 147 | N/A |
| 6/30/2023 | 729 | 138 | 51 | 149 | N/A |
| 3/31/2023 | 778 | 168 | 46 | 160 | N/A |
| 12/31/2022 | 802 | 186 | 39 | 172 | N/A |
| 9/30/2022 | 801 | 166 | 15 | 160 | N/A |
| 6/30/2022 | 779 | 159 | 41 | 141 | N/A |
| 3/31/2022 | 734 | 146 | 42 | 133 | N/A |
| 12/31/2021 | 671 | 128 | 48 | 119 | N/A |
| 9/30/2021 | 593 | 119 | 35 | 84 | N/A |
| 6/30/2021 | 509 | 100 | 40 | 83 | N/A |
| 3/31/2021 | 433 | 80 | 32 | 62 | N/A |
| 12/31/2020 | 366 | 60 | 36 | 63 | N/A |
| 9/30/2020 | 327 | 44 | 44 | 65 | N/A |
| 6/30/2020 | 302 | 31 | 42 | 66 | N/A |
| 3/31/2020 | 286 | 23 | 43 | 67 | N/A |
| 12/31/2019 | 270 | 21 | 44 | 67 | N/A |
| 9/30/2019 | 253 | 23 | 34 | 55 | N/A |
| 6/30/2019 | 233 | 27 | 34 | 53 | N/A |
| 3/31/2019 | 210 | 21 | 25 | 41 | N/A |
| 12/31/2018 | 194 | 17 | 19 | 33 | N/A |
| 9/30/2018 | 184 | 23 | 32 | 42 | N/A |
| 6/30/2018 | 171 | 23 | 14 | 21 | N/A |
| 3/31/2018 | 155 | 29 | 12 | 18 | N/A |
| 12/31/2017 | 141 | 28 | N/A | 17 | N/A |
| 9/30/2017 | 125 | 21 | N/A | 4 | N/A |
| 6/30/2017 | 113 | 18 | N/A | 5 | N/A |
| 3/31/2017 | 110 | 13 | N/A | 12 | N/A |
| 12/31/2016 | 105 | 12 | N/A | 8 | N/A |
| 9/30/2016 | 100 | 7 | N/A | 9 | N/A |
| 6/30/2016 | 96 | 8 | N/A | 17 | N/A |
| 3/31/2016 | 88 | 8 | N/A | 14 | N/A |
| 12/31/2015 | 84 | 9 | N/A | 15 | N/A |
| 9/30/2015 | 78 | 9 | N/A | 13 | N/A |
| 6/30/2015 | 74 | 8 | N/A | 13 | N/A |
| 3/31/2015 | 68 | 7 | N/A | 8 | N/A |
| 12/31/2014 | 64 | 8 | N/A | 18 | N/A |
| 9/30/2014 | 63 | 12 | N/A | 24 | N/A |
| 6/30/2014 | 66 | 16 | N/A | 24 | N/A |
| 3/31/2014 | 68 | 18 | N/A | 30 | N/A |
| 12/31/2013 | 68 | 16 | N/A | 26 | N/A |
| 9/30/2013 | 72 | 22 | N/A | 26 | N/A |
| 6/30/2013 | 68 | 18 | N/A | 22 | N/A |
Analyst Future Growth Forecasts
Earnings vs Savings Rate: RGEN's forecast earnings growth (60.5% per year) is above the savings rate (2.4%).
Earnings vs Market: RGEN's earnings (60.5% per year) are forecast to grow faster than the US market (14.1% per year).
High Growth Earnings: RGEN's earnings are expected to grow significantly over the next 3 years.
Revenue vs Market: RGEN's revenue (14.2% per year) is forecast to grow faster than the US market (8.2% per year).
High Growth Revenue: RGEN's revenue (14.2% per year) is forecast to grow slower than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: RGEN's Return on Equity is forecast to be low in 3 years time (5%).